MCK outlook supported by Q1 growth and $2.25B Precision acquisition
MCK said strategic focus on oncology and supply chain, including its $2.25B Precision Medicine Group acquisition, supports a positive outlook alongside robust Q1 growth, AI and technology investments, and biosimilar opportunities.
25B Precision Medicine Group acquisition, robust Q1 growth in key segments, and disciplined capital allocation. AI and technology investments, stable generics, and biosimilar opportunities support a positive out…